| Recruitment status | Terminated |
| Unique ID issued by UMIN | UMIN000034535 |
| Receipt No. | R000037479 |
| Scientific Title | Randomized clinical trial of antibiotic prophylaxis versus no intervention in muscle biopsy |
| Date of disclosure of the study information | 2018/10/18 |
| Last modified on | 2021/04/19 (Ver. 10) |
| Basic information | ||
| Public title | Randomized clinical trial of antibiotic prophylaxis versus no intervention in muscle biopsy | |
| Acronym | pros and cons antibiotic prophylaxis in muscle biopsy | |
| Scientific Title | Randomized clinical trial of antibiotic prophylaxis versus no intervention in muscle biopsy | |
| Scientific Title:Acronym | pros and cons antibiotic prophylaxis in muscle biopsy | |
| Region |
|
|
| Condition | ||
| Condition | Patients with planning muscle biopsy | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | The aim of this randomized clinical trial was to investigate whether or not a single intravenous dose of cefazolin (1g) should be performed to prevent wound infection for immunocompetent patients |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | The incidence and proportion of wound infection after muscle biopsy |
| Key secondary outcomes | 1) Background characteristics of patients
2) Adverse event of antibiotic 3) Wound score at the muscle biopsy performed region 4) characteristics of patients with wound infection 5) The relationship between days until the suture removal and the treatment with or without antibiotic 6) The relationship between body temperature and the treatment with or without antibiotic 7) The relationship between longitudinal changes of blood test (RBC, WBC, the subsets, PLT, Hb, BUN, Crea, TP, Alb, CK, AST, ALT, CRP) and the treatment with or without antibiotic 8) The relationship between longitudinal changes of blood test (RBC, WBC, the subsets, PLT, Hb, BUN, Crea, TP, Alb, CK, AST, ALT, CRP) and disease type, muscle biopsy performed region, operative duration of muscle biopsy and the value of manual muscle testing 9) The relationship between operative duration of muscle biopsy and disease type, muscle biopsy performed region, the value of manual muscle testing |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -no one is blinded |
| Control | No treatment |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | The group with single-dose antibiotic prophylaxis of cefazolin (1g) at muscle biopsy. | |
| Interventions/Control_2 | The group without antibiotic prophylaxis at muscle biopsy | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) Over 20 years old and less than 80 years old
2) Patient or proxy who can provide a informed consent |
|||
| Key exclusion criteria | 1) Patients who are not hospitalized in neurology
2) Less than 20 years old patients 3) Over 80 years old patients 4) Patients who are pregnant or might be pregnant 5) Immunocompromised patients 6) Patients with anamnesis of diabetes 7) Patients with over body mass index (BMI) of 25 kg/m2 8) Patients with experience of allergia for Cephalosporin antibiotic 9) Patients with anamnesis of anaphylactic shock for Cephalosporin 10) Patients with experience of hypersensitivity for local anesthetic such as anilide 11) Patients with over serum creatinine level 1.5 mg/dl 12) Patients with an infectious disease 13) Patient with treatment plan of immunosuppressive therapy immediately after muscle biopsy 14) Patients who have skin lesion at muscle biopsy planed region 15) Patients who are judged inappropriate for this trial by the attending physician |
|||
| Target sample size | 24 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Graduate School of Medical Sciences, Kumamoto University | ||||||
| Division name | Department of Neurology | ||||||
| Zip code | 860-8556 | ||||||
| Address | 1-1-1 Honjo Chuo-Ku, Kumamoto 860-8556, Japan | ||||||
| TEL | 096-373-5893 | ||||||
| y-stsh@pg8.so-net.ne.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Graduate School of Medical Sciences, Kumamoto University | ||||||
| Division name | Department of Neurology | ||||||
| Zip code | 860-8556 | ||||||
| Address | 1-1-1 Honjo Chuo-Ku, Kumamoto 860-8556, Japan | ||||||
| TEL | 096-373-5893 | ||||||
| Homepage URL | |||||||
| takamakt@gmail.com | |||||||
| Sponsor | |
| Institute | Kumamoto university |
| Institute | |
| Department | |
| Funding Source | |
| Organization | self-financing |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Kumamoto University Hospital, Advanced medical care unit |
| Address | 1-1-1 Honjo Chuo-Ku, Kumamoto 860-8556, Japan |
| Tel | 096-373-5966 |
| byi-senshin@jimu.kumamoto-u.ac.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | 2 |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Terminated | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000037479 |